Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Impax Transferring Products To Taiwan After GMP Warning Letter For U.S. Plant

This article was originally published in The Pink Sheet Daily

Executive Summary

Future applications involving the Hayward, Calif. plant targeted by warning letter on manufacturing practices may be stalled, but Phase III Parkinson's candidate IPX066 won't be affected, execs say.
Advertisement

Related Content

Impax CEO’s Strategy: Aggressive BD, Restructure R&D And Cut Costs
Impax Parkinson’s Therapy Suffers Manufacturing Setback During FDA Review
FDA Warning Letters Hit Inadequate Investigations and QC Failings
FDA Warning Letters Hit Inadequate Investigations and QC Failings
GMP Close-out Letter Program Shows Few Benefits After 20 Months
GMP Close-out Letter Program Shows Few Benefits After 20 Months
GSK Seeks Re-Entry To Parkinson's Market In Deal With Impax

Topics

Advertisement
UsernamePublicRestriction

Register

PS072472

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel